Jump to: navigation, search
Clinical data
ATCvet code
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass396.42 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Pradofloxacin


Most recent articles on Pradofloxacin

Most cited articles on Pradofloxacin

Review articles on Pradofloxacin

Articles on Pradofloxacin in N Eng J Med, Lancet, BMJ


Powerpoint slides on Pradofloxacin

Images of Pradofloxacin

Photos of Pradofloxacin

Podcasts & MP3s on Pradofloxacin

Videos on Pradofloxacin

Evidence Based Medicine

Cochrane Collaboration on Pradofloxacin

Bandolier on Pradofloxacin

TRIP on Pradofloxacin

Clinical Trials

Ongoing Trials on Pradofloxacin at Clinical

Trial results on Pradofloxacin

Clinical Trials on Pradofloxacin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Pradofloxacin

NICE Guidance on Pradofloxacin


FDA on Pradofloxacin

CDC on Pradofloxacin


Books on Pradofloxacin


Pradofloxacin in the news

Be alerted to news on Pradofloxacin

News trends on Pradofloxacin


Blogs on Pradofloxacin


Definitions of Pradofloxacin

Patient Resources / Community

Patient resources on Pradofloxacin

Discussion groups on Pradofloxacin

Patient Handouts on Pradofloxacin

Directions to Hospitals Treating Pradofloxacin

Risk calculators and risk factors for Pradofloxacin

Healthcare Provider Resources

Symptoms of Pradofloxacin

Causes & Risk Factors for Pradofloxacin

Diagnostic studies for Pradofloxacin

Treatment of Pradofloxacin

Continuing Medical Education (CME)

CME Programs on Pradofloxacin


Pradofloxacin en Espanol

Pradofloxacin en Francais


Pradofloxacin in the Marketplace

Patents on Pradofloxacin

Experimental / Informatics

List of terms related to Pradofloxacin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Pradofloxacin (trade name Veraflox) is a 3rd generation enhanced spectrum veterinary antibiotic of the fluoroquinolone class. It was developed by Bayer HealthCare AG, Animal Health GmbH, and received approval from the European Commission in April 2011 for prescription-only use in veterinary medicine for the treatment of bacterial infections in dogs and cats.[1]


Pradofloxacin was first discovered by chemists at Bayer in 1994 and patented in 1998. The name pradofloxacin was issued in December 2000 by the World Health Organization. Following submission for marketing authorisation to the European Medicines Agency (EMA) in 2004, the application was refused in 2006,[2] prompting further studies.

Having reviewed the additional studies, the EMA Committee for Medicinal Products for Veterinary Use (CVMP) recommended granting marketing authorisation of pradofloxacin by consensus in February 2011.[3] Marketing authorisation of pradofloxacin was granted by the European Commission in April 2011.[1]

Mechanism of action

The primary mode of action of fluoroquinolones involves interaction with enzymes essential for major DNA functions such as replication, transcription and recombination. The primary targets for pradofloxacin are the bacterial DNA gyrase and topoisomerase IV enzymes. Reversible association between pradofloxacin and DNA gyrase or DNA topoisomerase IV in the target bacteria results in inhibition of these enzymes and rapid death of the bacterial cell. The rapidity and extent of bacterial killing are directly proportional to the drug concentration.[4]

As a result, pradofloxacin is active against a wide range of Gram-positive and Gram-negative bacteria including anaerobic bacteria.[4]


As with all prescription veterinary medicine, advice on the use of pradofloxacin should always be sought from a suitably qualified veterinarian.[4]


Pradofloxacin was formerly indicated for the treatment of:[4]

  • wound infections and superficial and deep pyoderma caused by susceptible strains of the Staphylococcus intermedius group (including S. pseudintermedius),
  • acute urinary tract infections caused by susceptible strains of Escherichia coli and the Staphylococcus intermedius group (including S. pseudintermedius) and
  • as adjunctive treatment to mechanical or surgical periodontal therapy in the treatment of severe infections of the gingiva and periodontal tissues caused by susceptible strains of anaerobic organisms, for example Porphyromonas spp. and Prevotella spp.

but has since been shown to cause bone marrow suppression (resulting in severe neutropenia and thrombocytopenia) in dogs and is no longer recommended for use. [5]


Pradofloxacin is indicated for the treatment of:[4]

  • acute infections of the upper respiratory tract caused by susceptible strains of Pasteurella multocida, Escherichia coli and the Staphylococcus intermedius group (including S. pseudintermedius).
  • wound infections and abscesses caused by susceptible strains of Pasteurella multocida and the Staphylococcus intermedius group (including S. pseudintermedius) [for oral suspension only].

See also


  1. 1.0 1.1 "Community register of veterinary medicinal products". Retrieved 2012-06-20.
  2. "European Medicines Agency - Find medicine - Veraflox". Retrieved 2012-06-20.
  3. "European Medicines Agency - Find medicine - Veraflox". Retrieved 2012-06-20.
  4. 4.0 4.1 4.2 4.3 4.4 "Veraflox Summary of Product Characteristics" (PDF). April 2011.

External links